Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year.
Preclinical data suggests VIR-7832, a neutralising COVID-19 antibody, has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.
California’s Vir Biotechnology and GSK entered into a coronavirus collaboration in April 2020: using Vir’s proprietary monoclonal antibody platform tech to identify new and existing anti-viral antibodies for use against the COVID-19 pandemic. VIR-7832 is the second monoclonal antibody from the collaboration.
One of Britain’s biggest drugs companies said yesterday that it had more than ten potential blockbuster treatments in the late stages of development.Hal Barron, chief scientific officer and head of
On a day of major developments, Glaxosmithkline said it was joining an NHS study to test a breakthrough antibody treatment. The drug - known as Vir-7832 -could be a game changer.
Researchers among team testing new COVID-19 treatments miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.